| Description | AZD0424, an orally active compound characterized as a dual selective Src/Abl kinase inhibitor, exhibits potential antineoplastic activity[1] and promotes apoptosis and cell cycle arrest in lymphoma cells[2]. |
| In vitro | AZD0424 (5 μM; 48 hours) leads to increased G0/G1 cell cycle arrest in DOHH-2 and WSU-NHL cells, whereas the cell cycle progression of the nonsensitive cell lines Raji and Jurkat remains unaffected[2]. AZD0424 (1-5 μM; 24-48 hours) is emerged to be the more effective of the three tested inhibitors (AZM559756, AZD0530 and AZD0424), inducing the highest levels of apoptosis with the lowest concentrations in lymphoma cells[2]. |
| molecular weight | 528.99 |
| Molecular formula | C25H29ClN6O5 |
| CAS | 692054-06-1 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| References | 1. Woodcock VK, et al. A first-in-human phase I study to determine the maximum tolerated dose of the oral Src/ABL inhibitor AZD0424. Br J Cancer. 2018 Mar 20;118(6):770-776. 2. Nowak D, et al. Src kinase inhibitors induce apoptosis and mediate cell cycle arrest in lymphoma cells. Anticancer Drugs. 2007 Oct;18(9):981-95. |